Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is conducting a Phase 3 study titled ‘A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)’. The study aims to evaluate the long-term safety and tolerability of Rocatinlimab, a drug intended to treat moderate-to-severe atopic dermatitis in adults and adolescents.
The intervention being tested is Rocatinlimab, administered via subcutaneous injection, with the purpose of managing symptoms of atopic dermatitis. The study also includes a placebo group for comparison.
This interventional study is randomized with a parallel assignment model and double masking involving both participants and investigators. The primary goal is treatment-focused, aiming to provide insights into the drug’s efficacy and safety over an extended period.
The study began on May 31, 2023, and is currently recruiting participants. The primary completion and estimated overall completion dates are yet to be disclosed, with the last update recorded on July 24, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
Amgen’s ongoing study could influence its stock performance positively if Rocatinlimab demonstrates favorable results, potentially enhancing investor confidence. The study’s outcome might also impact the competitive landscape in the dermatology sector, where other companies are developing similar treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.